Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
Published: 2021-11-24 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0716 178.69% 12K
|
Health Technology
|
| O: 14515.38%
H: 0.0%
C: -1.95%
fda lung cancer phase 1 positive cancer phase 2
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
Published: 2023-07-31 (Crawled : 11:00) - globenewswire.com
RNAZ | $0.461 0.44% 0.43% 100K
|
Professional, Scientific, and T...
|
| O: 3986.21%
H: 1.43%
C: -7.17%
mc138 ttx-mc138 positive therapeutics results
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
Published: 2023-08-07 (Crawled : 14:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K
|
Health Technology
|
| O: 1090.48%
H: 0.0%
C: 0.0%
ph94 positive spray trial results
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
Published: 2024-02-28 (Crawled : 19:00) - biospace.com/
VANI | $1.81 8.38% 7.73% 88K
|
Manufacturing
|
| O: 499.01%
H: 28.93%
C: -38.18%
npm-115 ozempic obesity positive preclinical medical
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-09-28 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9201 -4.15% -4.33% 43K
|
n/a
|
| O: 480.71%
H: 12.06%
C: -41.08%
bnc210 positive topline trial results
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
SLNO | $40.32 7.41% 6.89% 420K
|
Health Technology
|
| O: 374.04%
H: 44.29%
C: 27.62%
positive therapeutics results study
La Rosa Acquires Seventh Real Estate Brokerage Franchisee with Revenue of $1.4 Million and Positive Cash Flow in 2023
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
LRHC | $1.5981 1.15% 16K
|
n/a
|
| O: 266.52%
H: 13.87%
C: -43.27%
rosa million revenue positive flow
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
Published: 2020-12-09 (Crawled : 17:00) - biospace.com/
XBIO | $3.76 7.32% 2.7K
|
Health Technology
|
| O: 258.33%
H: 51.16%
C: -18.09%
positive phase 3 trial
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
EYPT | News | $17.565 3.63% 3.5% 940K
|
Health Technology
|
| O: 232.83%
H: 2.0%
C: -16.64%
eyp-1901 positive pharmaceuticals topline trial
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
treatment fibrosis liver topline trial positive nash
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $22.0 -2.31% -2.36% 78K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Published: 2024-01-02 (Crawled : 20:00) - biospace.com/
LBPH | $20.27 8.57% 7.89% 500K
|
Manufacturing
|
| O: 206.47%
H: 39.72%
C: 35.82%
lp352 positive pharmaceuticals topline
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
AKLI | $0.2452 7.03% 6.57% 74K
|
|
| O: 193.1%
H: 13.69%
C: -30.36%
endeavorrx japan positive adhd trial results
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
BYSI | $2.26 7.11% 6.64% 110K
|
Health Technology
|
| O: 191.8%
H: 6.76%
C: -5.41%
treatment lung cancer positive results cancer topline trial plinabulin
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
Published: 2022-12-07 (Crawled : 12:20) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 181.13%
H: 0.0%
C: 0.0%
pra023 enabling positive phase 2b
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
Published: 2023-12-11 (Crawled : 13:00) - globenewswire.com
KTTA | $6.76 -1.19% 730
|
|
| O: 176.71%
H: 4.77%
C: -46.72%
pas-004 positive cancer preclinical therapeutics
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study
Published: 2023-04-12 (Crawled : 18:00) - biospace.com/
CELZ | $4.8301 0.21% 9.6K
|
|
| O: 160.33%
H: 5.56%
C: -30.56%
positive medical technology diabetes results study
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Published: 2023-12-03 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.14 0.47% 0.47% 32K
|
Health Technology
|
| O: 156.02%
H: 27.29%
C: -1.18%
ath434 disease positive parkinson’s therapeutics
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Published: 2023-12-04 (Crawled : 12:30) - globenewswire.com
ATHE | $2.14 0.47% 0.47% 32K
|
Health Technology
|
| O: 156.02%
H: 27.29%
C: -1.18%
ath434 disease positive parkinson’s therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.